article thumbnail

STAT+: Pharmalittle: We’re reading about Moderna’s RSV vaccine, Aurobindo problems, and more

STAT

We accept all manner of confidential communications and secret dossiers … New diabetes and weight loss drugs may benefit patients undergoing hip replacement without adding to complication risks , Reuters reports, citing preliminary data released at a meeting of orthopedic surgeons. Meanwhile, here are a few tidbits to digest.

Diabetes 297
article thumbnail

Incubators and innovation hubs: Accelerating entrepreneurship in life sciences

Express Pharma

As the pharmaceutical industry targets $130 billion by 2030 (7) and the medical devices market is eyeing $ 50 billion by 2030 (8), incubators and innovation hubs will be instrumental in harnessing this potential, empowering entrepreneurs to lead the nation’s growth in these sectors. India, with 47 per cent of its 1.4

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

The Benefits of Integrated CDMO Services: Streamlining Drug Development and Manufacturing

Drug Patent Watch

from 2023 to 2030. Simplified Communication and Coordination : Integrated CDMOs can improve cross-team coordination between research, development, and manufacturing, reducing the need for external hand-offs, technology transfer, and knowledge dissemination. .”

article thumbnail

UK £62 billion behind in R&D global investment share, report reveals

European Pharmaceutical Review

The report suggested health research is a key area for R&D investment to align activity with broader social goals, communicate a clear strategic direction and improve R&D funding by crowding novel investment. . percent of GDP by 2030, to level with R&D investment in Sweden, the US and Taiwan. billion over a decade.

article thumbnail

Eli Lilly to help fund cold chain initiative

European Pharmaceutical Review

.” “Efforts to expand access to medicines, especially insulin, are only beneficial when effective cold chain systems are in place to keep them at the right temperature on their way to patients,” commented Leigh Ann Pusey, Executive Vice President of corporate affairs and communications for Lilly.

article thumbnail

Scientific evidence ‘on demand’? Proceedings from an expert roundtable

pharmaphorum

The ways in which we communicate and consume information are constantly transforming. In 2020, the challenges of the COVID-19 pandemic greatly accelerated the pace of this evolution, with wide-reaching effects on many aspects of medical communications. Q1: What are some ways in which data dissemination has evolved in 2020?

article thumbnail

Lilly and EVA Pharma to aid affordable insulin access in Africa

European Pharmaceutical Review

Lilly’s 30×30 initiative aims to improve access to quality healthcare for 30 million people living in limited-resource settings, annually, by 2030. Communication with WHO encourage implementation of and accountability for the commitments and contributions toward improving access to insulin.